Last reviewed · How we verify
Troxevasin
Troxevasin is a Small molecule drug developed by Center for Vascular Pathology, Moscow. It is currently in Phase 2 development.
Troxevasin is a hydroxyethylrutoside, a derivative of rutin, which is a flavonoid found in the Japanese pagoda tree. It is being studied in clinical trials, including one for its efficacy and safety in children with venous malformations, alongside other phlebotonic drugs.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Troxevasin |
|---|---|
| Sponsor | Center for Vascular Pathology, Moscow |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
- LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Troxevasin CI brief — competitive landscape report
- Troxevasin updates RSS · CI watch RSS
- Center for Vascular Pathology, Moscow portfolio CI
Frequently asked questions about Troxevasin
What is Troxevasin?
Who makes Troxevasin?
What development phase is Troxevasin in?
Related
- Manufacturer: Center for Vascular Pathology, Moscow — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing